FY2028 Earnings Estimate for TLX Issued By Wedbush

Key Points

• Wedbush has issued a FY2028 EPS estimate for Telix Pharmaceuticals at $0.89 per share, significantly higher than the current consensus estimate of $0.24.
• The stock has an average target price of $22.33 and has received multiple "buy" ratings from analysts, indicating positive sentiment towards Telix Pharmaceuticals.
• Shares of Telix Pharmaceuticals traded at $12.09 as of the report, with a one-year high of $30.36 and a low of $10.50.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Research analysts at Wedbush issued their FY2028 EPS estimates for shares of Telix Pharmaceuticals in a report issued on Thursday, August 21st. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of $0.89 per share for the year. Wedbush has a "Outperform" rating and a $22.00 price target on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share.

A number of other equities research analysts have also issued reports on the stock. HC Wainwright assumed coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 target price for the company. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Telix Pharmaceuticals presently has an average rating of "Buy" and an average target price of $22.33.

Telix Pharmaceuticals Trading Up 10.2%

Shares of NASDAQ TLX opened at $12.09 on Friday. Telix Pharmaceuticals has a one year low of $10.50 and a one year high of $30.36. The firm has a fifty day moving average of $14.55 and a 200 day moving average of $16.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals during the first quarter worth about $170,000. IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals in the second quarter valued at approximately $213,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals in the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals in the second quarter valued at approximately $297,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.